PMID- 16684123
OWN - NLM
STAT- MEDLINE
DCOM- 20060915
LR  - 20151119
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 36
IP  - 6
DP  - 2006 Jun
TI  - Soluble CD40L in patients with morbid obesity: significant reduction after 
      bariatric surgery.
PG  - 395-401
AB  - BACKGROUND: Morbid obesity is associated with increased cardiovascular morbidity 
      and mortality. Recent studies suggest that soluble CD40 Ligand (sCD40L) may play 
      a pathogenetic role in atherothrombotic complications in cardiovascular disease 
      as well as in inflammation and thrombosis. As morbid obesity is closely 
      associated with chronic inflammation and insulin resistance (IR), it was of 
      interest to study sCD40L in patients with morbid obesity before and after massive 
      weight loss induced by bariatric surgery. PATIENTS AND METHODS: A total of 34 
      patients (mean age 40 +/- 12 years) with morbid obesity were studied before and 
      27.2 months after bariatric surgery. High sensitivity assays were used to measure 
      concentrations of fasting sCD40L, monocyte-chemoattractant-protein-1 (MCP-1) and 
      high-sensitive C-reactive protein (hsCRP). To investigate the associations of 
      concentration changes of the parameters studied, differences between pre- and 
      post-operative data were assessed and tested by univariate and multivariate 
      linear regression analysis. RESULTS: After a mean weight loss of 33.1 +/- 18.4 
      kg, circulating sCD40L decreased significantly from (3.7 +/- 1.5) ng mL(-1) to 
      (2.2 +/- 0.7) ng mL(-1), (P < 0.001). The decline in sCD40L after weight loss 
      correlated significantly with the decrease in fasting insulin, 2-h insulin, HOMA 
      insulin resistance (HOMA-IR), triglycerides, and the inflammatory biomarkers 
      MCP-1 and hsCRP. CONCLUSIONS: We have shown a marked decrease in circulating 
      sCD40L in association with an improvement of both insulin resistance and chronic 
      inflammation in morbidly obese patients after bariatric surgery. As high sCD40L 
      was shown to predict cardiovascular death and myocardial infarction in several 
      prospective studies, the observed marked lowering of sCD40L might be of clinical 
      relevance in morbidly obese patients.
FAU - Schernthaner, G-H
AU  - Schernthaner GH
AD  - Department of Internal Medicine II, Medical University of Vienna, Vienna, 
      Austria. gerit.schernthaner@meduniwien.ac.at
FAU - Kopp, H-P
AU  - Kopp HP
FAU - Krzyzanowska, K
AU  - Krzyzanowska K
FAU - Kriwanek, S
AU  - Kriwanek S
FAU - Koppensteiner, R
AU  - Koppensteiner R
FAU - Schernthaner, G
AU  - Schernthaner G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Insulin)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - C-Reactive Protein/metabolism
MH  - CD40 Ligand/*blood
MH  - Chemokine CCL2/blood
MH  - Female
MH  - *Gastroplasty
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/*blood/*surgery
MH  - Postoperative Period
MH  - Solubility
MH  - Weight Loss
EDAT- 2006/05/11 09:00
MHDA- 2006/09/16 09:00
CRDT- 2006/05/11 09:00
PHST- 2006/05/11 09:00 [pubmed]
PHST- 2006/09/16 09:00 [medline]
PHST- 2006/05/11 09:00 [entrez]
AID - ECI1649 [pii]
AID - 10.1111/j.1365-2362.2006.01649.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2006 Jun;36(6):395-401. doi: 10.1111/j.1365-2362.2006.01649.x.